Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
111,111,111
-
Number of holders
-
236
-
Total 13F shares, excl. options
-
91,569,880
-
Shares change
-
-1,141,569
-
Total reported value, excl. options
-
$2,728,867,320
-
Value change
-
-$6,541,149
-
Put/Call ratio
-
30.62%
-
Number of buys
-
107
-
Number of sells
-
-113
-
Price
-
$29.8
Significant Holders of NovoCure Ltd - Common Stock (NVCR) as of Q4 2024
297 filings reported holding NVCR - NovoCure Ltd - Common Stock as of Q4 2024.
NovoCure Ltd - Common Stock (NVCR) has 236 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 91,569,880 shares
of 111,111,111 outstanding shares and own 82.41% of the company stock.
Largest 10 shareholders include FMR LLC (16,230,139 shares), BlackRock, Inc. (13,026,498 shares), VANGUARD GROUP INC (11,796,109 shares), Capital International Investors (8,873,902 shares), Capital World Investors (4,815,529 shares), Soleus Capital Management, L.P. (2,739,704 shares), STATE STREET CORP (2,641,445 shares), GEODE CAPITAL MANAGEMENT, LLC (2,400,182 shares), T. Rowe Price Investment Management, Inc. (1,690,441 shares), and PRICE T ROWE ASSOCIATES INC /MD/ (1,683,818 shares).
This table shows the top 236 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.